Compare INSM & EL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | EL |
|---|---|---|
| Founded | 1988 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 27.3B |
| IPO Year | 2000 | 2007 |
| Metric | INSM | EL |
|---|---|---|
| Price | $144.17 | $76.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 20 |
| Target Price | ★ $201.17 | $97.60 |
| AVG Volume (30 Days) | 2.1M | ★ 4.4M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 1.83% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | N/A | ★ $14,326,000,000.00 |
| Revenue This Year | $182.31 | $7.51 |
| Revenue Next Year | $65.19 | $4.08 |
| P/E Ratio | ★ N/A | $134.51 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $63.81 | $56.66 |
| 52 Week High | $212.75 | $121.64 |
| Indicator | INSM | EL |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 45.51 |
| Support Level | $142.99 | $66.22 |
| Resistance Level | $149.08 | $93.70 |
| Average True Range (ATR) | 4.92 | 2.68 |
| MACD | -1.49 | 1.54 |
| Stochastic Oscillator | 17.78 | 75.54 |
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Estée Lauder is a leader in the global prestige beauty market, participating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and others (5%). Top-selling brands include Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 31% of revenue from the Americas, 37% from Europe, the Middle East and Africa (including travel retail), and 32% from Asia-Pacific. Estée Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.